Protecting investment in biologic medicines - biological medicines, biosimilars and the challenges they pose

By Ric Morgan

In brief

This series of articles is directed towards the part of biotech that is 'pharmaceutical', rather than diagnostic or bioengineering technologies, and, in particular, towards biologic medicines.

These are medicines that have been made or modified using biological systems, ie living organisms or their derivatives.

>> Download a PDF copy of the paper.